Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
fordoctors:cyp450_genotype [2019/06/11 18:42]
info_firmalab [Drug Metabolism and Drug Dosis Recomendations]
fordoctors:cyp450_genotype [2019/06/11 18:49] (current)
info_firmalab [CYP2D6]
Line 32: Line 32:
  
 This test is focused on the prediction of or confirmation of cause ineffective medication for patients with chronic pain using narcotic analgesic medications. ​ This test is focused on the prediction of or confirmation of cause ineffective medication for patients with chronic pain using narcotic analgesic medications. ​
-The test will identified extensive (EM, normal), ultrarapid (UM), Intermediate Metabolizers (IMs), and poor metabolizers (PM). Roughly 10% of the population are PMs, they have no 2D6 enzymatic activity. Another 35% of the population are considered IMs with decreased activity. Still another 1-3% of people are UM.+The test will be identified extensive (EM, normal), ultrarapid (UM), Intermediate Metabolizers (IMs), and poor metabolizers (PM). Roughly 10% of the population are PMs, they have no 2D6 enzymatic activity. Another 35% of the population are considered IMs with decreased activity. Still another 1-3% of people are UM.
  
 The ultrarapid metabolizer (UM) phenotype is recognized as a cause of therapeutic inefficacy of antidepressant. Duplication of the functional CYP2D6 gene has been observed, which may result in ultrarapid metabolism of SSRIs and other drugs. Up to 13 copies of CYP2D6 have been reported. For these patients a pro-drug will be converted rapidly resulting in a quick spike in the serum levels but may also have a reduced duration. UMs cases of life-threatening toxicity have been reported with the prodrugs tramadol and codeine. For drugs that are metabolzied to inactive forms, UMs may require more frequent doses or alternative forms of pain relief. The ultrarapid metabolizer (UM) phenotype is recognized as a cause of therapeutic inefficacy of antidepressant. Duplication of the functional CYP2D6 gene has been observed, which may result in ultrarapid metabolism of SSRIs and other drugs. Up to 13 copies of CYP2D6 have been reported. For these patients a pro-drug will be converted rapidly resulting in a quick spike in the serum levels but may also have a reduced duration. UMs cases of life-threatening toxicity have been reported with the prodrugs tramadol and codeine. For drugs that are metabolzied to inactive forms, UMs may require more frequent doses or alternative forms of pain relief.
Back to top
Copyright ©2015-2019. All rights reserved.